Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
GM Explores Defense Manufacturing Partnership With Lockheed Martin 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
OpenAI's $34B Spending Pushes AI Market Leadership Ahead of IPO 
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Disaster or digital spectacle? The dangers of using floods to create social media content 
ASX Proposes New Share Dilution Limits for Public Takeovers 
AI is driving down the price of knowledge – universities have to rethink what they offer 
Why the future of marijuana legalization remains hazy despite high public support 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Fed Chair Kevin Warsh Signals Policy Overhaul as Hawkish Rate Outlook Rattles Markets 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
